Choroidal thickness measurements with optical coherence tomography in branch retinal vein occlusion

• Published in: International journal of ophthalmology Vol. 9; no. 5; pp. 725 - 729
• Main Authors: Coban-Karatas, Muge, Altan-Yaycioglu, Rana, Ulas, Burak, Sizmaz, Selcuk, Canan, Handan, Sariturk, Cagla
• Format: Journal Article
• Language: English
• Published: China International Journal of Ophthalmology Press 18-05-2016; Press of International Journal of Ophthalmology (IJO PRESS)
• Subjects: branch retinal vein occlusion; choroidal thickness; Clinical Research; macular edema; optical coherence tomography; ranibizumab; branch retinal vein occlusion; choroidal thickness; macular edema; optical coherence tomography; ranibizumab
• ISSN: 2222-3959; 2227-4898
• DOI: 10.18240/ijo.2016.05.16

AIM： To evaluate central macular thickness（CMT） and mean choroidal thickness（MCT） in eyes with branch retinal vein occlusion（BRVO）, before and after ranibizumab treatment using spectral domain-optical coherence tomography（SD-OCT）.·METHODS： Forty-two patients with unilateral BRVO and macular edema were included in this study. There were 25 men and 17 women. Using SD-OCT, choroidal thickness was measured at 500 μm intervals up to 1500μm temporal and nasal to the fovea. MCT was calculated based on the average of the 7 locations. All the eyes with BRVO were treated with intravitreal ranibizumab（0.5 mg/0.05 m L）. Comparisons between the BRVO and fellow eyes were analyzed using Mann-Whitney U test. Preinjection and post-injection measurements were analyzed using Wilcoxon test and repeated measure analysis.· RESULTS： At baseline, there was a significant difference between the BRVO and fellow eyes in MCT[BRVO eyes 245（165-330） μm, fellow eyes 229（157-327） μm]and CMT [BRVO eyes 463（266-899） μm, fellow eyes 235（148-378） μm（P =0.041, 0.0001, respectively）]. Following treatment, CMT [295（141-558） μm] and MCT [229（157-329） μm] decreased significantly compared to the baseline measurements（P =0.001, 0.006, respectively）.Also BCVA（log MAR） improved significantly（P=0.0001） in the BRVO eyes following treatment. After treatment CMT[BRVO eyes 295（141-558） μm, fellow eyes 234（157-351） μm]and MCT [BRVO eyes 229（157-329） μm, fellow eyes 233（162-286） μm] values did not reveal any significant difference in BRVO eyes and fellow eyes（P=0.051, 0.824,respectively）.· CONCLUSION： In eyes with BRVO, CMT and MCT values are greater than the fellow eyes, and decrease significantly following ranibizumab injection.